Loading
A phase 3 trial of Pemetrexed, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by mAbxience Research S.L., active and no longer recruiting.
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) is a phase 3 interventional study registered as NCT06687369 by mAbxience Research S.L., with 726 participants planned, started 2024-12-30 and due to reach its primary completion in 2026-08-31. Interventions recorded: MB12 (Proposed Pembrolizumab Biosimilar), EU-sourced Keytruda®, US-sourced Keytruda®, Pemetrexed, Carboplatin. Conditions listed: Non Squamous Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.